These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


113 related items for PubMed ID: 1879060

  • 21. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects.
    Cleare AJ, Murray RM, O'Keane V.
    Neuropsychopharmacology; 1996 May; 14(5):349-54. PubMed ID: 8703303
    [Abstract] [Full Text] [Related]

  • 22. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men.
    Coccaro EF, Berman ME, Kavoussi RJ, Hauger RL.
    Biol Psychiatry; 1996 Aug 01; 40(3):157-64. PubMed ID: 8830948
    [Abstract] [Full Text] [Related]

  • 23. Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study.
    Monteleone P, Tortorella A, Borriello R, Cassandro P, Maj M.
    Biol Psychiatry; 1999 Jun 15; 45(12):1606-11. PubMed ID: 10376122
    [Abstract] [Full Text] [Related]

  • 24. Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus.
    Nappi RE, Sances G, Brundu B, Ghiotto N, Detaddei S, Biancardi C, Polatti F, Nappi G.
    Neuroendocrinology; 2003 Jul 15; 78(1):52-60. PubMed ID: 12869800
    [Abstract] [Full Text] [Related]

  • 25. Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT.
    Levy AD, Li Q, Van de Kar LD.
    Neuropharmacology; 1994 Jul 15; 33(3-4):335-42. PubMed ID: 7984271
    [Abstract] [Full Text] [Related]

  • 26. Blunted fenfluramine-evoked prolactin secretion in hypertensive rats.
    Stocker SD, Muldoon MF, Sved AF.
    Hypertension; 2003 Oct 15; 42(4):719-24. PubMed ID: 12885788
    [Abstract] [Full Text] [Related]

  • 27. Central 5-hydroxytryptamine2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat.
    Chaouloff F, Gunn SH, Young JB.
    J Pharmacol Exp Ther; 1992 Mar 15; 260(3):1008-16. PubMed ID: 1545373
    [Abstract] [Full Text] [Related]

  • 28. Lack of effect of hydrocortisone treatment on d-fenfluramine-mediated prolactin release.
    Young AH, Rue J, Odontiadis J, Cowen PJ.
    Psychopharmacology (Berl); 1998 Mar 15; 136(2):198-200. PubMed ID: 9551777
    [Abstract] [Full Text] [Related]

  • 29. Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle.
    O'Keane V, Dinan TG.
    J Clin Endocrinol Metab; 1992 Jul 15; 75(1):11-4. PubMed ID: 1618997
    [Abstract] [Full Text] [Related]

  • 30. Plasma prolactin, adrenocorticotrophic hormone and cortisol after administration of d-fenfluramine or placebo to healthy subjects.
    Gorard DA, Taylor TM, Medbak SH, Perry LA, Libby GW, Farthing MJ.
    Int Clin Psychopharmacol; 1993 Jul 15; 8(2):123-8. PubMed ID: 8393895
    [Abstract] [Full Text] [Related]

  • 31. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function.
    O'Keane V, Dinan TG.
    Am J Psychiatry; 1991 Aug 15; 148(8):1009-15. PubMed ID: 1853948
    [Abstract] [Full Text] [Related]

  • 32. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
    Grimes EM, Thompson IE, Taymor ML.
    Acta Endocrinol (Copenh); 1975 Aug 15; 79(4):625-34. PubMed ID: 1098349
    [Abstract] [Full Text] [Related]

  • 33. Plasma oxytocin in response to pharmaco-challenge to D-fenfluramine and placebo in healthy men.
    Lee R, Garcia F, van de Kar LD, Hauger RD, Coccaro EF.
    Psychiatry Res; 2003 May 30; 118(2):129-36. PubMed ID: 12798977
    [Abstract] [Full Text] [Related]

  • 34. Prolactin response to secretin during the spontaneous menstrual cycle in women.
    Holst N, Jenssen TG, Burhol PG, Haug E.
    Gynecol Obstet Invest; 1991 May 30; 31(1):37-41. PubMed ID: 1672662
    [Abstract] [Full Text] [Related]

  • 35. Endocrine and amine responses to D,L-fenfluramine in normal subjects.
    Mitchell PB, Smythe GA.
    Psychiatry Res; 1991 Nov 30; 39(2):141-53. PubMed ID: 1686811
    [Abstract] [Full Text] [Related]

  • 36. Differences between morning and afternoon hormonal responses to D-fenfluramine in healthy humans.
    Monteleone P, Bortolotti F, Orazzo C, Serino I, Maj M.
    Psychoneuroendocrinology; 1997 Feb 30; 22(2):79-87. PubMed ID: 9149330
    [Abstract] [Full Text] [Related]

  • 37. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder.
    FitzGerald M, Malone KM, Li S, Harrison WM, McBride PA, Endicott J, Cooper T, Mann JJ.
    Am J Psychiatry; 1997 Apr 30; 154(4):556-8. PubMed ID: 9090347
    [Abstract] [Full Text] [Related]

  • 38. Neuroendocrine and neurochemical responses to novelty stress in young and old male F344 rats: effects of d-fenfluramine treatment.
    Handa RJ, Cross MK, George M, Gordon BH, Burgess LH, Cabrera TM, Hata N, Campbell DB, Lorens SA.
    Pharmacol Biochem Behav; 1993 Sep 30; 46(1):101-9. PubMed ID: 8255900
    [Abstract] [Full Text] [Related]

  • 39. Serotonergic function in cocaine addicts: prolactin responses to sequential D,L-fenfluramine challenges.
    Buydens-Branchey L, Branchey M, Hudson J, Rothman M, Fergeson P, McKernin C.
    Biol Psychiatry; 1999 May 15; 45(10):1300-6. PubMed ID: 10349036
    [Abstract] [Full Text] [Related]

  • 40. Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation.
    Saletu B, Barbanoj MJ, Anderer P, Sieghart W, Grünberger J.
    Methods Find Exp Clin Pharmacol; 1993 Jun 15; 15(5):291-312. PubMed ID: 8412414
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 6.